TheraCryf

TheraCryf plc is a forward-thinking clinical stage therapeutics company dedicated to developing innovative treatments in oncology and behavioural brain disorders. Located in Nether Alderley, Cheshire, at Alderley Park, Congleton Road, SK10 4TG, GB, TheraCryf is committed to generating compelling data sets, with the ultimate goal of partnering its programs with mid-size to large pharmaceutical companies.

TheraCryf's strategic focus involves leveraging its expertise to develop and commercialise a combined portfolio of advanced therapeutics. The company’s leading clinical asset, SFX-01, is a patented sulforaphane-based medicine. Furthermore, TheraCryf incorporates neuropsychiatry assets utilising novel chemistry to target crucial areas in brain health, supported by composition of matter patent cover.

Operating since 2007, TheraCryf’s core mission encompasses a broad portfolio of pharmaceuticals aimed at addressing critical health challenges. We invite the management team at TheraCryf to create a customized and exclusive company showcase and product listing on our platform, to further highlight their innovative contributions to the biotechnology field.